Scott Ribich

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde et al. · The Lancet Oncology · 2018 · 597 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Elayne Chan-Penebre, Kristy G. Kuplast, Christina R. Majer et al. · Nature Chemical Biology · 2015 · 533 citations

Vitro Potency, Signal Transduction, Medicine +10

Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis

Eric E. Gardner, Benjamin H. Lok, Valentina E. Schneeberger et al. · Cancer Cell · 2017 · 513 citations · Full text

Oncology, Chemosensitive Relapse, Medicine +9

Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP

Amy K. Walker, Fajun Yang, Karen Jiang et al. · Genes & Development · 2010 · 351 citations · Full text

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien et al. · Cancer Cell · 2019 · 333 citations · Full text

Cancer Research, Mtap Loss, Medicine +10